Macroplastique Implants
PMA P040050
Active
Valid until
No expiry
FDA recalls
None found
Documents
Trust
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA PMAAPPR | NumberP040050 | Date30 Oct 2006 | StatusActive |
Official records
- FDA PMA database P040050
From the FDA record
FDA PMA P040050
- Received by the FDA
- 22 Dec 2004
- FDA decision
- 30 Oct 2006
- FDA review time
- 677 days from receipt to decision
- Docket number
- 06M-0457
APPROVAL FOR MACROPLASTIQUE IMPLANTS. THE DEVICE IS INDICATED FOR TRANSURETHRAL INJECTION IN THE TREATMENT OF ADULT WOMEN DIAGNOSED WITH STRESS URINARY INCONTINENCE (SUI) PRIMARILY DUE TO INTRINSIC SPHINCTER DEFICIENCY (ISD).
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA PMA Active
Specification
- Generic name
- AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE
- PMA number
- FDA product code
- LNM
- Device class
- Class III
- Advisory committee
- Gastroenterology, Urology
- FDA decision
- APPR Approved
Overview
AI-generated summary, 18 Sep 2026
Macroplastique Implants are an injectable bulking agent designed for gastro-urology use. This medical device is indicated for transurethral injection in adult women who have been diagnosed with stress urinary incontinence primarily due to intrinsic sphincter deficiency.
This device is manufactured by Uroplasty, LLC and has received FDA premarket approval. It is intended for clinical use by medical professionals to address specific urological conditions in female patients.
Devices cleared under P040050
Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.
| UDI-DI | Size and differences | |||
|---|---|---|---|---|
| Macroplastique Implants MPQ-2.5 | MPQ-2.5 / MPQ-2.5 | 08717591240266 | — | On the market |
Similar devices
Other devices filed under FDA product code LNM (Agent, Bulking, Injectable For Gastro-Urology Use).
- Deflux Injectable Gel by Palette Life Sciences Inc.
- Deflux Metal Needle 3.7 FR x 23 G (tip) x 350 mm DX1201 by Palette Life Sciences Inc.
- Bulkamid Urethral Bulking System by Boston Scientific
- Durasphere Injectable Bulking Agent by Carbon Medical Technologies, Inc.
- Enteryx Procedure Kit by Boston Scientific
- Coaptite Injectable Implant by Merz North America, Inc.
- Bard URYX Urethral Bulking Agent by C. R. Bard, Inc.
- Contigen Bard Collagen Implant by Allergan
Other devices from Uroplasty, LLC
Questions
AI-generated answers, 18 Sep 2026
What is the primary use of Macroplastique Implants?
Macroplastique Implants are used as an injectable bulking agent for the treatment of stress urinary incontinence in adult women, specifically when the condition is caused by intrinsic sphincter deficiency.
How are Macroplastique Implants administered?
The device is administered via transurethral injection by a qualified medical professional to provide the necessary bulking effect for treating incontinence.
Who manufactures Macroplastique Implants?
Macroplastique Implants are manufactured by Uroplasty, LLC, based in Minnetonka, Minnesota.